• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

择期经皮冠状动脉介入治疗(PCI)前 P2Y12 抑制剂负荷时间与心肌坏死的预防

P2Y Inhibitor Loading Time Before Elective PCI and the Prevention of Myocardial Necrosis.

机构信息

ACTION Study Group, Sorbonne Université, INSERM UMRS1166, Hôpital Pitié-Salpêtrière (AP-HP), Paris, France; Département de Cardiologie, CHU de Caen, Caen, France.

Département de Cardiologie, CHU de Caen, Caen, France.

出版信息

Can J Cardiol. 2024 Jan;40(1):31-39. doi: 10.1016/j.cjca.2023.08.028. Epub 2023 Sep 3.

DOI:10.1016/j.cjca.2023.08.028
PMID:
37660934
Abstract

BACKGROUND

There are dated and conflicting data about the optimal timing of initiation of P2Y inhibitors in elective percutaneous coronary intervention (PCI). Peri-PCI myocardial necrosis is associated with poor outcomes. We aimed to assess the impact of the P2Y inhibitor loading time on periprocedural myocardial necrosis in the population of the randomized Assessment of Loading With the P2Y Inhibitor Ticagrelor or Clopidogrel to Halt Ischemic Events in Patients Undergoing Elective Coronary Stenting (ALPHEUS) trial, which compared ticagrelor with clopidogrel in high-risk patients who received elective PCI.

METHODS

The ALPHEUS trial divided 1809 patients into quartiles of loading time. The ALPHEUS primary outcome was used (type 4 [a or b] myocardial infarction or major myocardial injury) as well as the main secondary outcome (type 4 [a or b] myocardial infarction or any type of myocardial injury).

RESULTS

Patients in the first quartile group (Q1) presented higher rates of the primary outcome (P = 0.01). When compared with Q1, incidences of the primary outcome decreased in patients with longer loading times (adjusted odds ratio [adjOR], 0.70 [0.52.-0.95]; P = 0.02 for Q2; adjOR 0.65 [0.48-0.88]; P < 0.01 for Q3; adjOR 0.66 [0.49-0.89]; P < 0.01 for Q4). Concordant results were found for the main secondary outcome. There was no interaction with the study drug allocated by randomization (clopidogrel or ticagrelor). Bleeding complications (any bleeding ranging between 4.9% and 7.3% and only 1 major bleeding at 48 hours) and clinical ischemic events were rare and did not differ among groups.

CONCLUSIONS

In elective PCI, administration of the oral P2Y inhibitor at the time of PCI could be associated with more frequent periprocedural myocardial necrosis than an earlier administration. The long-term clinical consequences remain unknown.

摘要

背景

关于择期经皮冠状动脉介入治疗(PCI)中开始使用 P2Y 抑制剂的最佳时机,存在过时且相互矛盾的数据。PCI 围术期心肌坏死与不良结局相关。我们旨在评估在随机评估替格瑞洛或氯吡格雷负荷剂量对接受择期冠状动脉支架置入术的高危患者缺血事件的影响(ALPHEUS)试验人群中,P2Y 抑制剂负荷时间对围手术期心肌坏死的影响,该试验比较了替格瑞洛与氯吡格雷在接受择期 PCI 的高危患者中的疗效。

方法

ALPHEUS 试验将 1809 例患者分为负荷时间四分位组。采用 ALPHEUS 主要终点(4 型[ a 或 b ]心肌梗死或主要心肌损伤)和主要次要终点(4 型[ a 或 b ]心肌梗死或任何类型的心肌损伤)进行分析。

结果

第 1 四分位组(Q1)患者的主要终点发生率较高(P=0.01)。与 Q1 相比,负荷时间较长的患者主要终点发生率降低(校正优势比[adjOR],0.70[0.52.-0.95];P=0.02 对于 Q2;adjOR 0.65[0.48-0.88];P<0.01 对于 Q3;adjOR 0.66[0.49-0.89];P<0.01 对于 Q4)。主要次要终点也有一致的结果。与随机分配的研究药物(氯吡格雷或替格瑞洛)之间没有相互作用。出血并发症(任何出血 4.9%-7.3%,48 小时仅 1 例大出血)和临床缺血事件罕见,且各组之间无差异。

结论

在择期 PCI 中,PCI 时给予口服 P2Y 抑制剂可能与更频繁的围手术期心肌坏死相关,而不是更早的给药。长期临床后果尚不清楚。

相似文献

1
P2Y Inhibitor Loading Time Before Elective PCI and the Prevention of Myocardial Necrosis.择期经皮冠状动脉介入治疗(PCI)前 P2Y12 抑制剂负荷时间与心肌坏死的预防
Can J Cardiol. 2024 Jan;40(1):31-39. doi: 10.1016/j.cjca.2023.08.028. Epub 2023 Sep 3.
2
Blunting periprocedural myocardial necrosis: Rationale and design of the randomized ALPHEUS study.钝抑围手术期心肌坏死:随机 ALPHEUS 研究的原理和设计。
Am Heart J. 2020 Jul;225:27-37. doi: 10.1016/j.ahj.2020.04.017. Epub 2020 Apr 29.
3
Ticagrelor versus clopidogrel in elective percutaneous coronary intervention (ALPHEUS): a randomised, open-label, phase 3b trial.替格瑞洛与氯吡格雷用于择期经皮冠状动脉介入治疗(ALPHEUS):一项随机、开放标签、3b 期临床试验。
Lancet. 2020 Nov 28;396(10264):1737-1744. doi: 10.1016/S0140-6736(20)32236-4. Epub 2020 Nov 14.
4
Ticagrelor vs Clopidogrel in Clopidogrel-Naive Patients With Chronic Coronary Syndrome.替格瑞洛与氯吡格雷在氯吡格雷初治慢性冠脉综合征患者中的比较。
JACC Cardiovasc Interv. 2024 Jun 24;17(12):1413-1421. doi: 10.1016/j.jcin.2024.04.015. Epub 2024 Jun 5.
5
Ticagrelor vs Clopidogrel for Complex Percutaneous Coronary Intervention in Chronic Coronary Syndrome.替格瑞洛与氯吡格雷用于慢性冠状动脉综合征患者复杂经皮冠状动脉介入治疗。
JACC Cardiovasc Interv. 2024 Feb 12;17(3):359-370. doi: 10.1016/j.jcin.2023.12.011.
6
Physician and Hospital Utilization of P2Y12 Inhibitors in ST-Segment-Elevation Myocardial Infarction in the United States: A Study From the National Cardiovascular Data Registry's Research to Practice Initiative.美国ST段抬高型心肌梗死患者中P2Y12抑制剂的医生及医院使用情况:一项来自国家心血管数据注册中心“研究到实践”倡议的研究
Circ Cardiovasc Qual Outcomes. 2020 Mar;13(3):e006275. doi: 10.1161/CIRCOUTCOMES.119.006275. Epub 2020 Mar 11.
7
Efficacy and Safety of Loading Doses With P2Y12-Receptor Antagonists in Patients Without Dual Antiplatelet Therapy Undergoing Elective Coronary Intervention.未行双联抗血小板治疗的择期经皮冠状动脉介入治疗患者中应用 P2Y12 受体拮抗剂负荷剂量的疗效和安全性。
J Cardiovasc Pharmacol. 2019 Jan;73(1):56-59. doi: 10.1097/FJC.0000000000000632.
8
Optimal Timing of P2Y12 Inhibitor Loading in Patients Undergoing PCI: A Meta-Analysis.经皮冠状动脉介入治疗(PCI)患者中 P2Y12 抑制剂负荷治疗的最佳时机:一项荟萃分析。
Thromb Haemost. 2019 Jun;119(6):1000-1020. doi: 10.1055/s-0039-1683421. Epub 2019 Mar 27.
9
Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention: The TAILOR-PCI Randomized Clinical Trial.基因指导的口服 P2Y12 抑制剂选择与常规氯吡格雷治疗对经皮冠状动脉介入治疗后缺血结局的影响:TAILOR-PCI 随机临床试验。
JAMA. 2020 Aug 25;324(8):761-771. doi: 10.1001/jama.2020.12443.
10
Periprocedural Outcomes According to Timing of Clopidogrel Loading Dose in Patients Who Did Not Receive P2Y Inhibitor Pretreatment.未接受 P2Y 抑制剂预处理的患者氯吡格雷负荷剂量给药时机的围手术期结局。
Circ Cardiovasc Interv. 2019 Mar;12(3):e007445. doi: 10.1161/CIRCINTERVENTIONS.118.007445.